Loading...
Loading...
Genzyme, a Sanofi company,
SNY announced today that
the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^®
(teriflunomide) 14 mg as a new once-daily, oral treatment indicated for
patients with relapsing forms of multiple sclerosis (MS). The TGA approval
will enable health professionals to prescribe AUBAGIO 14 mg in Australia,
which is now the second country to gain marketing authorization for the
treatment, following FDA approval in September.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in